依鲁替尼联合CD19 CAR-T治疗依鲁替尼失败的CLL可行且有效
该试点研究纳入19例依鲁替尼失败的复发难治CLL患者,在CD19 CAR-T治疗期间同步使用依鲁替尼。方案耐受良好,4周总缓解率83%,61%达骨髓MRD阴性;同步依鲁替尼组CRS更轻、CRS相关细胞因子更低,但1年PFS与未同步组无显著差异。
要点
- 依鲁替尼失败CLL中,同步依鲁替尼联合CD19 CAR-T耐受良好,68%按计划完成依鲁替尼未减量。
- 4周总缓解率83%,61%经IGH测序达骨髓MRD阴性。
- 同步依鲁替尼降低CRS严重度和CRS相关细胞因子,且不影响CAR-T体内扩增。
核心结论
- 对依鲁替尼失败的复发难治CLL,CD19 CAR-T同步依鲁替尼方案耐受良好、CRS严重度低,并获得高比例经IGH测序的MRD阴性缓解。
研究设计与样本
- 试点研究,纳入19例依鲁替尼失败后接受CD19 CAR-T的复发难治CLL患者。
- 依鲁替尼计划在白细胞分离前至少2周开始,CAR-T输注后继续至少3个月。
- 中位既往治疗线数为5,17例(89%)具有高危细胞遗传学(17p缺失和/或复杂核型)。
主要发现
- 13例(68%)按计划接受依鲁替尼且未减量。
- 按2018 iwCLL标准,4周总缓解率为83%,61%经IGH测序达骨髓MRD阴性。
- 在该亚组中,1年总生存概率为86%,1年无进展生存(PFS)概率为59%。
- 与未同步依鲁替尼的CAR-T患者相比,同步组CRS严重度更低、CRS相关血清细胞因子浓度更低,而体内CAR-T扩增相当。
- 所有可评估患者中,同步与未同步依鲁替尼的1年PFS概率分别为38%和50%(P = .91)。
关键数值与推荐
- 4周总缓解率采用2018 iwCLL标准评估,为83%。
- 骨髓MRD阴性采用IGH测序评估,为61%。
- 同步与未同步依鲁替尼的1年PFS概率分别为38%和50%,P = .91。
临床怎么用
- 对依鲁替尼失败的复发难治CLL,可考虑CD19 CAR-T同步依鲁替尼以降低CRS严重度并提高MRD阴性缓解率。
- 同步依鲁替尼未显著改善1年PFS,临床决策需结合患者个体情况。
局限性
- 为试点研究,样本量19例,结论需更大规模研究验证。
- 同步与未同步依鲁替尼的PFS比较非随机,P = .91。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We previously reported durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) patients treated with CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T-cell immunotherapy after ibrutinib failure. Because preclinical studies showed that ibrutinib could improve CAR T cell-antitumor efficacy and reduce cytokine release syndrome (CRS), we conducted a pilot study to evaluate the safety and feasibility of administering ibrutinib concurrently with CD19 CAR T-cell immunotherapy. Nineteen CLL patients were included. The median number of prior therapies was 5, and 17 patients (89%) had high-risk cytogenetics (17p deletion and/or complex karyotype). Ibrutinib was scheduled to begin ≥2 weeks before leukapheresis and continue for ≥3 months after CAR T-cell infusion. CD19 CAR T-cell therapy with concurrent ibrutinib was well tolerated; 13 patients (68%) received ibrutinib as planned without dose reduction. The 4-week overall response rate using 2018 International Workshop on CLL (iwCLL) criteria was 83%, and 61% achieved a minimal residual disease (MRD)-negative marrow response by IGH sequencing. In this subset, the 1-year overall survival and progression-free survival (PFS) probabilities were 86% and 59%, respectively. Compared with CLL patients treated with CAR T cells without ibrutinib, CAR T cells with concurrent ibrutinib were associated with lower CRS severity and lower serum concentrations of CRS-associated cytokines, despite equivalent in vivo CAR T-cell expansion. The 1-year PFS probabilities in all evaluable patients were 38% and 50% after CD19 CAR T-cell therapy, with and without concurrent ibrutinib, respectively (P = .91). CD19 CAR T cells with concurrent ibrutinib for R/R CLL were well tolerated, with low CRS severity, and led to high rates of MRD-negative response by IGH sequencing.
引用
- Gauthier J, Hirayama AV, Purushe J, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020. PMID: 32076701. doi:10.1182/blood.2019002936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。